A diagnosis of pancreatic cancer often leads patients and families to search for every possible treatment option. One therapy generating significant attention is daraxonrasib (RMC-6236), an investigational medication being studied for patients with advanced pancreatic cancer driven by KRAS mutations.
Missouri Cancer Associates is proud to be one of the practices participating in the Expanded Access Program (EAP) for daraxonrasib, giving eligible patients in central Missouri the opportunity to receive this promising therapy before it becomes commercially available.
What is daraxonrasib?
Daraxonrasib (also known as RMC-6236) is an investigational oral targeted therapy designed to treat cancers driven by mutations in the RAS signaling pathway, particularly KRAS mutations, which are found in the majority of pancreatic cancers.
Unlike traditional chemotherapy, targeted therapies are designed to interfere with specific molecular changes that help cancer cells grow and spread. Researchers are studying daraxonrasib to determine whether it can improve outcomes for patients whose cancer has progressed after standard treatment.
Because daraxonrasib is still under investigation, it has not yet been approved by the U.S. Food and Drug Administration (FDA).
Why Is Daraxonrasib So Difficult to Access?
If you’ve been researching treatment options online, you may have discovered that daraxonrasib (RMC-6236) is not widely available.
That’s because the medication is still considered investigational, meaning it has not yet received FDA approval. Most patients cannot simply ask their doctor to prescribe it.
Currently, patients generally have two ways to access daraxonrasib:
- Participation in an eligible clinical trial.
- An Expanded Access Program (EAP) for patients who meet strict medical criteria and cannot participate in a clinical trial.
Only select cancer centers have been approved to participate in the Expanded Access Program. Missouri Cancer Associates is proud to be one of those sites, allowing eligible patients in central Missouri to be evaluated for this promising therapy close to home.
Why is everyone talking about it?
Daraxonrasib has attracted national attention because of encouraging results from recent clinical studies involving patients with previously treated metastatic pancreatic cancer.
In one recent Phase III study, patients receiving daraxonrasib had a median overall survival of 13.2 months, compared with 6.7 months for patients receiving standard chemotherapy. While additional review is still underway, these results have created optimism among oncologists and researchers looking for better treatment options for pancreatic cancer.
It’s important to remember that every patient is different. Treatment decisions should always be made with your oncology team based on your cancer, overall health, previous treatments, and molecular testing results.
Who may be eligible?
The Expanded Access Program is intended for select patients who:
- Have advanced or metastatic pancreatic cancer
- Have exhausted available standard treatment options
- Are unable to participate in an active clinical trial
- Meet additional medical eligibility criteria established by the program sponsor
Eligibility is determined on an individual basis after a thorough evaluation by your oncology team.
What is an Expanded Access Program?
An Expanded Access Program (sometimes called compassionate use) allows eligible patients with serious illnesses to receive investigational therapies outside of a clinical trial when no comparable treatment options are available.
These programs are carefully regulated and are designed to provide access while researchers continue to gather information about the therapy’s safety and effectiveness.
Why Missouri Cancer Associates?
At Missouri Cancer Associates, we believe patients shouldn’t have to leave central Missouri to access innovative cancer care.
Our growing research program provides patients with access to clinical trials, investigational therapies, and Expanded Access Programs across multiple cancer types—including pancreatic, breast, lung, colon, bladder, and others.
Next Steps
If you or a loved one has pancreatic cancer and would like to learn whether daraxonrasib may be an option, we encourage you to speak with your oncologist or contact Missouri Cancer Associates.
Our physicians can review your medical history, discuss available treatment options, and determine whether you may qualify for the Expanded Access Program or another clinical research opportunity.
Every patient’s journey is unique, and our goal is to provide compassionate, personalized care while offering access to the latest advances in cancer treatment—close to home.
Frequently Asked Questions
Is daraxonrasib FDA approved?
No. Daraxonrasib (RMC-6236) is currently an investigational therapy undergoing regulatory review.
Can I receive daraxonrasib at Missouri Cancer Associates?
Missouri Cancer Associates participates in the Expanded Access Program, but patients must meet specific eligibility requirements.
Do I need a KRAS mutation?
Because daraxonrasib targets RAS-driven cancers, molecular testing may be part of determining whether the treatment is appropriate for you.
How do I learn if I’m eligible?
Schedule an appointment with one of our medical oncologists at Missouri Cancer Associates. Your physician will review your diagnosis, previous treatments, and overall health to determine whether daraxonrasib or another clinical trial may be a good fit.